Split (1)

train · 13.8M rows

sentence stringlengths 1 23.5k ⌀
We hire on merit and are committed to employing and engaging talented people irrespective of their race, gender, religion, sexual orientation, age, marital status, national origin, present or past history of mental or physical disability and any other factors not related to a person’s ability to perform a role.
During the year, we conducted focus groups and peerto-peer discussions to evaluate opportunities to strengthen our culture of belonging.
We established an employee-led initiative – the Black Employees Advisory Board in the US – and a Diversity, Equity and Belonging Task Force to direct a more inclusive approach to employee recruitment, retention and promotion.
demonstrate strong Environmental, Social and Governance (ESG) practices as measured against globally recognised standards.
such as human rights, anti-corruption, environmental performance, health and safety, and community engagement.
This year, our score increased from ranking as compared to other member companies from the 57th to the 78th percentile.
We continue to score above the averages for both healthcare and pharmaceuticals sectors in all three ESG categories.
The challenges that arose in support for patients and communities more important than ever.
Finding ways to enable access to medicine is an important responsibility for companies like ours and is something we have always taken seriously.
We believe that when worldclass medicine is put within people’s reach, it doesn’t just transform their lives, but it enriches our communities.
Addressing unmet healthcare needs through our medicine donation programme Through our medicine donation programme, we direct support to those that need it most; including low-income groups, displaced persons, children with lifethreatening illness, and patients without sufficient medical coverage.
In response to the challenges that arose in of marginalised communities that resulted from the pandemic, our medicine donations more than doubled compared to 2018, reaching $4.1 million (value based on cost of goods).
We strengthened our existing relationships with our partners including Direct Relief, Dispensary of Hope, Americares, and the National Children’s Cancer Society.
We also established new partnerships with Save the Children and others to ensure our donations of essential medicines continue into the future.
Our people worked together to support local hospitals, clinics and pharmacies in order to improve patient access to vital healthcare facilities.
Provided sterilisation tools to Supported sanitisation of 1,000 clinics and 1,500 pharmacies Distributed medical supplies to nine hospitals Responding to the medical emergency following the Beirut explosion The explosion that tore through Beirut on August 4, 2020 resulted in the tragic loss of hundreds of lives and wid...
We responded immediately and worked alongside our partners to provide critical medicines and basic necessities to those most affected.
Raising awareness of COVID-schools in Egypt and Tunisia Our support for the Royal Health Awareness Society (RHAS) Healthy Schools programme began in 2018 to encourage healthy behaviours and habits for students in public schools across Jordan.
Since reached more than 8,000 students across 12 schools.
In restrictions caused by the pandemic, we supported RHAS with the implementation of online, interactive engagement of students, reaching more than 3,000 students across four schools.
In Egypt, we developed a community engagement programme that focused on children’s education, and specifically on children that were forced to drop out of school due to the difficulties of the pandemic.
Through the programme, our employees in Egypt visited community schools, impacting 600 students.
We also organised an educational forum in collaboration with the National Council for Mothers and Children to discuss obstacles faced by children during the difficult period.
Our employees distributed kits for students that included personal safety equipment and stationery for school use.
In Tunisia, our employees visited more than distributed personal protective equipment and gave awareness lectures to more than 1,000 students.
TREE is a teacher training and development programme that aims to improve the quality of education for Syrian refugees in Jordan.
The programme enables educators to more effectively address the trauma and unique learning needs of displaced children by incorporating psychosocial support and emotional learning approaches for students.
The aim is to provide training and support for more than 745,000 students through the programme.
We are thrilled about our new partnership with Hikma.
They are strengthening a ground-breaking programme that provides crucial assistance to teachers in Jordan and the refugee children they teach.
In with CareerVillage, a web platform and online community connecting 4.5 million students seeking careeradvice.
Through a combination of financial support and employee volunteering, we were able to complete construction of schools and libraries that will enable students to improve their access to education.
In Sudan, the renovation and infrastructure development of two schools will impact around students.
In Portugal, in support of the reopening of schools following lockdowns, we distributed essential school supplies and safety equipment to four elementary schools near our facility.
We also distributed supplies for our employees’ children.
Through the campaign, more than received educational and safety equipment.
In response to COVID-job losses and furloughs, Hikma US launched an employee matching donation campaign to support our neighbors in need.
Donations were provided to our local food bank and pantry partners in New Jersey and Ohio, who saw unprecedented increases in demand for food due to the pandemic.
Together, with Hikma employees, we donated over meals in 2020.
The economic impact of the pandemic placed immense strain on the most vulnerable segments of our societies.
In response, we have focused much of our outreach towards providing basic necessities to those most affected.
Partnerships to strengthen food security in Jordan Our partnerships with organisations dedicated to food security, such as Tkiyet Um Ali, Ta’alof Al Khair, and the Haya Cultural Centre became more essential during the pandemic.
During the year, we increased our efforts to distribute food parcels containing basic nutritional items to low-income groups across the country.
Um Ali since providing meals to more than 18,600 people.
Enabling our people Our people are our most valuable asset.
We adapted health and safety measures to address the unprecedented challenges of the COVID-continued expanding our global learning and development programme by providing more readily accessible digital resources to all employees.
In response to the pandemic, it was essential for us to take measures that protect the safety of our employees while maintaining continuity of our manufacturing operations and supply of medicines.
Distributed personal protective equipment to all employees and implemented screening measures including daily health checks and temperature monitoring.
to reduce interaction and strengthen social distancing between departments and shifts, and instituted restrictions on travel and in-person meetings in line with public health authority guidelines.
As part of the We Are Hikma campaign, we established webinars and online resources for employees on themes related to mental wellbeing, stress management and general awareness.
Spotlight: Home visits project for breast cancer screening Through our partnership with the King Hussein Cancer Foundation, our support for the home visits project enables under-privileged women typically in rural, inaccessible locations to receive breast cancer screening and follow-up consultations when needed.
In screening of 150 women through the programme.
Our online support sessions received As our people coped with the circumstances of 2020, managing lockdown restrictions and heightened safety situations, we provided a range of online resources to support their mental and physical health and wellbeing.
We organised awareness sessions, online webinars and discussion forums for our employees to engage with experts and others about relevant health and safety issues.
Our annual campaign engages employees and raises awareness about the value of early detection and treatment.
As part of our campaign, we offered employees self-screening training, educational lectures and facilitated appointments with doctors.
We also distributed educational materials, and donated encouragement cards and kits of hope to hundreds of breast cancer patients worldwide.
As a pharmaceutical company, our primary obligation is to ensure our products are as safe as possible for the patients who use them.
We gather comprehensive information about our products’ safety so that we can take proactive measures to minimise risks to our patients.
Every medicine has the potential to produce adverse events for patients.
Not all adverse events are known at the time of approval of a new medicine.
Some may only be discovered post-approval after a medicine has been used by a large number of patients.
Our Approach The health and safety of our patients is at the heart of what we do.
We have globally-aligned processes to detect, evaluate and communicate any change to the benefit-risk ratio of our products and to implement timely corrective and preventative actions.
When needed in the pre-approval phase, we submit a registration dossier to relevant authorities that includes risk management plans (RMPs) detailing the risk management system proposed to identify, characterise and minimise the safety risks.
Once marketing approval is granted for regulatory authorities for products that need RMPs, we implement risk minimisation measures and measure their effectiveness.
We currently have over 650 registered compounds globally.
We receive the reports from healthcare professionals, consumers, regulatory authorities, literature, studies and social media.
These include periodic safety update reports (PSURs) and periodic adverse drug event reports (PADERs), which provide an up-to-date overview of the product’s safety worldwide and an assessment of its benefit-risk ratio.
These reports are submitted at regular intervals to health authorities, who validate that the benefits of our products outweigh their risks and confirm that they remain safe to stay on the market.
We continually monitor for changes to pharmacovigilance requirements to ensure we stay ahead of the regulatory landscape.
We also conduct signal detection activities for our products monthly to proactively detect safety issues.
Any new safety signals are examined by our Drug Safety Committee (DSC), which decides what further action is needed.
Pharmacovigilance is monitored at the highest levels of our business and is included in Globally registered compounds 5,000+ Submissions overseen annually Our commitment to patient safety 21Hikma Pharmaceuticals PLC \| Sustainability Report 2020 our enterprise risk management process, which is overseen by the Executive ...
We use a global safety database to support our process for adverse event management and electronic reporting.
This helps ensure that our pharmacovigilance activities remain in compliance with global safety reporting obligations.
We continuously invest in our pharmacovigilance team and strive to build their capabilities, as well as broader awareness across the organisation.
In eLearning course, Pharmacovigilance 101, to all Hikma employees through our Learning Management System (LMS).
In addition, the global pharmacovigilance team also launched a new Group Pharmacovigilance Policy taking effect 15 July 2020.
Under this policy, all Hikma employees must report to the PV department any adverse event, adverse drug reaction or other safety report relating to Hikma products as soon as possible, and in all cases not later than one business day.
How we perform To ensure our pharmacovigilance system is achieving its objectives, we monitor our worldwide compliance metrics every month.
In within legally-specified timelines remained high at over 98% and 100%, respectively, which is consistent with industry peers.
Health authority regulatory reporting (aggregate reports) Our pharmacovigilance audit strategy ensures that risk-based audits are performed annually, in line with our pharmacovigilance audit plan.
Audits cover all processes and activities performed by our Global Pharmacovigilance team, affiliates and third parties, such as distributors, service providers and partners.
Our pharmacovigilance audit programme helps ensure our compliance with regulations and provides opportunities to continuously improve our existing systems.
In 2020, we audited 3 affiliates and Corporate PV.
In addition, we underwent a pharmacovigilance regulatory inspection by the Saudi Food and Drug Authority, and one audit from a partner.
Monitoring and minimising our environmental impact We are committed to making our operations more energy efficient and environmentally responsible.
We continue to achieve progress with our environmental performance.
We are improving the way we monitor our impact, pursuing projects that reduce our footprint and working towards aligning with the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD).
the UK government’s policy on Streamlined Energy and Carbon Reporting.
We continue to invest in energy efficiency projects and renewable energy systems at multiple sites, and are adopting hybrid and electric vehicles where feasible.
— We quantify and report our organisational GHG emissions in alignment with the World Resources Institute’s Greenhouse Gas Protocol Corporate Accounting and Reporting Standard and in alignment with the Scope 2 Guidance.
Non-manufacturing facilities with less than 150 staff, including our UK office are not included as they fall below our materiality threshold.
Joint ventures with less than 50% holding are not included as we do not have operational control.
— Emissions from the consumption of electricity are reported in tCO2e.
— Reported data from previous years are revised as we continue to improve the quality of our data collection and analysis.
Renewable energy purchased and generated Our renewable energy capacity We continue to invest in renewable energy infrastructure to reduce our footprint and long-term overhead costs.
We currently have solar photovoltaic systems in four locations – three in Jordan and one in Portugal.
We also purchase electricity generated by renewables in Portugal and Sudan.

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.